Connect Biopharma Holdings (CNTB) Net Margin (2024 - 2026)
Connect Biopharma Holdings' (CNTB) quarterly Net Margin came in at 624.42% in Q2 2026, up 2624849.0% year-over-year from N/an in Q2 2025, and up 94.56% quarter-over-quarter from 11478.11% in Q1 2026.
Powered by 
Analysis
Connect Biopharma Holdings (CNTB) Net Margin (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings has disclosed Net Margin across 3 years of filings, most recently posting 624.42% for Q2 2026.
- In Q2 2026, Net Margin rose 2624849.0% year-over-year to 624.42%; the TTM figure through Jun 2026 stood at 2336.3% (down 4862.0% YoY), while the FY2025 annual figure was 86687.5%, down 8662747.0% from the prior year.
- Net Margin came in at 624.42% for Q2 2026 at Connect Biopharma Holdings, up from 11478.11% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 624.42% in Q2 2026 to a low of 107500.0% in Q3 2025.
- Average Net Margin over 3 years is 24801.28%, with a median of 6377.02% recorded in 2024.
- Year-over-year, Net Margin tumbled 10644372 bps in 2025 and surged 2624849 bps in 2026.
- Over 3 years, Net Margin stood at 1275.93% in 2024, then tumbled by 8325 bps to 107500.0% in 2025, then jumped by 99 bps to 624.42% in 2026.
- Per Business Quant data, the three most recent Net Margin figures were 624.42% in Q2 2026, 11478.11% in Q1 2026, and 107500.0% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,152.98% |
| 10 | Connect Biopharma Holdings | 129.86 Mn | 129.86 Mn | - | -624.42% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -624.42% |
| Mar 31, 2026 | -11,478.11% |
| Sep 30, 2025 | -107,500.00% |
| Jun 30, 2025 | -26,872.92% |
| Dec 31, 2024 | -1,275.93% |
| Sep 30, 2024 | -1,056.28% |